The Astra Zeneca vaccine turmoil as headlines today and tomorrow
This has moved from a very small number of clotting events w/ a vast denominator -> international dismay, characterized as "political" in the update👇-> to (sadly) a crisis in confidence nytimes.com/2021/03/16/wor…
I'd like to see fully dataset for the clotting events, particularly the 7 cavernous sinus thrombosis cases in Germany (out of 1.6 million vaccinated), all cases of immune thrombocytopenia (ITP). ITP has been very rarely reported, associated w/ Pfizer/Moderna vaccines /2
Of course, association ≠ causation. More common events like DVT/PE (majority of the reports) would be fully expected and v unlikely related to vaccination. Releasing all the data (rather than EMA/WHO statements) can help bolster trust for the medical community to patients /f
Make that 3 days in a row
Anti-platelet antibodies identified in Norway cases vg.no/nyheter/innenr… via @SvendsenAre
The key point is how unusual many of these rare clotting events are, as detailed in @ScienceMagazine prior article
• • •
Missing some Tweet in this thread? You can try to
force a refresh
NEW RECORD and a big jump from the one set yesterday
4.58 vaccine doses in the US today!
And a new Y-axis.
That's 4.58 million.
It's remarkable, to say the least.
It reflects tens of thousand of volunteers, health professionals to get this done. On Saturday, no less.🙏🙏
It is= to getting jabs in over 2.2 % of American adults in 1 day
👍👏👏💪
If we prevent the B.1.1.7 strain hit in the next few weeks, which is looking more likely each day, it'll be largely attributable to how this country stepped up with vaccination.
Now (@CDCgov) almost 21% of all Americans, and 63% age ≥ 65 with ≥ 1 dose. Phenomenal progress.
The spectrum of covid illness and effect of the vaccines in clinical trials 1. The trials were designed and powered for protection from mild to moderate illness. Not severe infections. Not asymptomatic infections. Not hospitalizations or deaths. Not #LongCovid.
2. The Table summarizes the data to point out how few severe endpoints occurred. The largest N of endpoints was in the J&J trial and <10% fell into the "severe" category. All together for over 152,000 participants, <100 severe endpoints.
3. We registered concern last fall about this matter, that there will be inadequate events/statistical power to judge severe infections and outcomes nytimes.com/2020/09/22/opi…
Is a new Oregon variant functionally different?
It's too early to tell nytimes.com/2021/03/05/hea…
I coined the term "scariant" because there's a mixed bag of real troubling variants (like B.1.1.7, P.1, B.1.351) + many that are not adequately characterized, may lack need for concern
The @JNJNews vaccine FDA briefing documents are out, so we now can see how well this single adenovirus vector vaccine dose works fda.gov/media/146217/d… 1. It is efficacious, overall 66%, but not as high as the mRNA vaccines (even in US with D614G strain).
2. While 85% efficacy was seen for severe infections, there was some falloff in participants > 60 yrs of age
3. A look at asymptomatic infections (carrier state) suggests the efficacy for reducing that is similar to overall efficacy
There's a problem with labelling the California variant (B.1.427/B.1.429) "increasingly dangerous" when there isn't even a preprint published and we're watching dramatic descent in cases, hospitalization and deaths despite its high frequency latimes.com/science/story/…
More @nytimes on this today, without the "dangerous" stuff.
But I am not convinced there is any meaningful functional difference for this "California variant" in light of above comment (the real laboratory is what is going on in California) nytimes.com/2021/02/23/hea… by @carlzimmer